The 6 analysts offering 12-month price forecasts for Viridian Therapeutics Inc have a median target of 35.00, with a high estimate of 44.00 and a low estimate of 26.00. The median estimate represents a +142.38% increase from the last price of 14.44.
The current consensus among 6 polled investment analysts is to Buy stock in Viridian Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.10
Reporting Date Nov 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.